ClinicalTrials.gg
Enrolling by invitationNCT06355102Updated Oct 9, 2024

The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics

An observational study in Sudden Sensorineural Hearing Loss and Tinnitus, sponsored by The First Affiliated Hospital with Nanjing Medical University. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.

Started
2024
the only one that year
Observational
3 of 18
2 open now
Primary completion
2025-12
later than 3 of 10 live
Registered
10th of 18
by date
Lead sponsor
1 of 18
The First Affiliated Hospital with Nanjing Medical University

Among the 18 studies in Hearing Loss, Sudden with a site in China, this one is the only one that started in 2024, is one of 3 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 10th registered.

Hearing Loss, Sudden

66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.

Browse Hearing Loss, Sudden studies →

Open to participants now

11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hearing Loss, Sudden with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the factors and mechanisms underlying tinnitus generation and chronification in patients with sudden sensorineural hearing loss (SSNHL) . The main questions it aims to answer are:

  • What are the peripheral and central influencing factors that contribute to tinnitus in patients with SSNHL?
  • Can serum metabolic biomarkers be identified to predict and monitor tinnitus prognosis in these patients?

Participants in this study will include patients with SSNHL and tinnitus, patients with SSNHL without tinnitus, and healthy subjects. They will be asked to undergo a series of assessments, including audiological tests, vestibular function examinations, and functional magnetic resonance imaging (fMRI). Additionally, blood samples will be collected for metabolomics analysis.

Investigators will compare the brain functional states and serum metabolite profiles of patients with SSNHL and tinnitus to those without tinnitus. Morever, tinnitus symptom characteristics, audiological outcomes, and brain functional states will be assessed during time.

Read the detailed description

The incidence rate of tinnitus is very high globally and shows an increasing trend year by year. Sudden sensorineural hearing loss (SSNHL) , a prevalent otolaryngological emergency, often coincides with tinnitus among its patient population. This condition can significantly impact individuals' interpersonal relationships, work performance, and daily functioning, ultimately leading to a diminished quality of life and even psychological disturbances, such as anxiety and depression. Consequently, it is imperative to expore the mechanisms underlying the emergence and chronicity of tinnitus following SSNHL, and to devise targeted intervention strategies aimed at preventing the chronicity of tinnitus.

This study aims to enroll 30 patients with SSNHL accompanied by tinnitus, 30 patients with SSNHL without tinnitus, and 30 healthy subjects. Investigators will record general demographic information, tinnitus symptom characteristics, audiological examinations, vestibular function tests, and other information for each group during the acute phase of SSNHL onset. Using functional magnetic resonance imaging (fMRI), investigators will compare the brain functional states of patients with SSNHL accompanied by tinnitus and those without tinnitus during the acute phase to investigate the peripheral influencing factors and central mechanisms of tinnitus production. Additionally, investigators will conduct metabolomics analysis to compare the serum metabolite profiles of these two patient groups to identify serum metabolic biomarkers and prognostic biomarkers for tinnitus in patients with SSNHL accompanied by tinnitus. Furthermore, this study will conduct follow-up assessments on the subjects at 1 month, 3 months, and 6 months after the onset of SSNHL, reviewing changes in their symptom characteristics, audiological examinations, and fMRI. At 6 months after the onset, patients will be divided into a tinnitus recovery group and a tinnitus non-recovery group based on their tinnitus recovery status. Investigators will compare the general demographic characteristics, audiological examinations, and brain functional MRI findings between the two groups to explore the role and mechanisms of brain plasticity changes in the recovery or chronicity of tinnitus in patients with SSNHL.

03

Conditions studied

  • Sudden Sensorineural Hearing Loss
  • Tinnitus

Keywords

  • Sudden sensorineural hearing loss
  • Tinnitus chronicity
  • Functional magnetic resonance imaging
  • Metabolomics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with SSNHL and individuals undergoing physical examination at the Department of Otolaryngology, the First Affiliated Hospital of Nanjing Medical University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Group of SSNHL with Tinnitus:

    1. Age between 18 and 65 years old;
    2. Meets the diagnostic criteria for SSNHL; untreated within 5 days after onset;
    3. Presence of tinnitus;
    4. Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
  2. Group of SSNHL without Tinnitus:

    1. Age between 18 and 65 years old;
    2. Meets the diagnostic criteria for SSNHL; untreated within 5 days after onset;
    3. Absence of tinnitus;
    4. Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
  3. Healthy Control:

    1. Age between 18 and 65 years old;
    2. Normal hearing screening results;
    3. Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  1. Previous diagnosis of otic organic diseases such as otitis media, cholesteatoma of the middle ear, Ménière's disease, acoustic neuroma, hereditary deafness, inner ear malformations, etc.; history of ear surgery; long-term exposure to noise; use of ototoxic drugs;
  2. Presence of brain organic diseases such as cerebral infarction, brain tumor, or for functional magnetic resonance imaging (fMRI) during nuclear magnetic resonance (NMR) examination;
  3. History of mental illness, including anxiety, depression, insomnia, etc.;
  4. Individuals unable to cooperate due to severe mental factors.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • SSNHL with Tinnitus

    Patients diagnosed with sudden sensorineural hearing loss accompanied with acute occuring tinnitus symptoms.

    Other: Conventional treatment and care

  • SSNHL without Tinnitus

    Patients diagnosed with sudden sensorineural hearing loss without acute occuring tinnitus symptoms.

    Other: Conventional treatment and care

  • Health Control

    Healthy subjects with normal hearing and no tinnitus.

    Other: Conventional treatment and care

Interventions

  • OtherConventional treatment and care

    Conventional treatment and care

06

What researchers measure

Primary outcomes

  1. Brain function states

    Fractional amplitude of low-frequency fluctuation, regional homogeneity, and functional connection will be compared among different groups using fMRI. Morever, the connections between the default mode network (DMN), central executive network (CEN), and salience network (SN) will be assessed through fMRI.

    Time frame: Acute phase (within 5 days after onset), 1 month, 3 months, and 6 months after onset

  2. Serum metabolomics

    Serum metabolic profiles and characteristics will be gained and compared in patients SSNHL with or with tinnitus, using LC-MS metabolomics technology.

    Time frame: Acute phase (within 5 days after onset)

07

Study locations

1 site
  • Department of Otolaryngology, the First Affiliated Hospital, Nanjing Medical University
    Nanjing, Jiangsu 210029, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2025, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Apr 9, 2024
StartActual
Apr 15, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Mar 31, 2026
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06355102
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Apr 15, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Oct 9, 2024

Study contacts

Liyuan Zhang, M.D.
principal investigator · Department of Otolaryngology, the First Affiliated Hospital, Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion